Details for 2019151147
Up to date per 05.04.2026
Actions
Details for 2019151147
Granted/Registered
European Patent
16.09.2020 A
02.03.2022 B1
01.08.2013
US
201361861198 P
08.11.2013
US
201361901732 P
30.01.2014
US
201461933632 P
C07K 16/28 20060101AFI20210715BHEP
Owner
Five Prime Therapeutics, Inc.111 Oyster Point Boulevard South San Francisco, CA 94080US
Representative
Representative
Häupl & Ellmeyer KG, PatentanwaltskanzleiMariahilfer Straße 50 (Eingang Kirchengasse 1)1070 WienAT
Inventor
HARDING, ThomasFive Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080US
PIERCE, KristenFive Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080US
PATIL, NamrataFive Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080US
BRENNAN, ThomasFive Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080US
HAMBLETON, JulieFive Prime Therapeutics, Inc. 111 Oyster Point Boulevard South San Francisco, CA 94080US
Information about Fees